Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.14
-0.0900-2.13%
Volume:762.57K
Turnover:3.19M
Market Cap:129.54M
PE:-1.00
High:4.29
Open:4.23
Low:4.12
Close:4.23
52wk High:50.40
52wk Low:4.12
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.00
T/O Rate:4.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.59
PE(LYR):-1.45

Loading ...

NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq

TIPRANKS
·
Sep 10

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

GlobeNewswire
·
Sep 10

Obsidian Therapeutics participates in a conference call with William Blair

TIPRANKS
·
Sep 10

Summit Therapeutics Shares Rise After Upgrade From Jefferies

MT Newswires Live
·
Sep 10

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

MT Newswires Live
·
Sep 09

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

GlobeNewswire
·
Sep 09

GeneDx, Beren Therapeutics launch NPC GenomeComplete

TIPRANKS
·
Sep 09

Cardiol Therapeutics to Showcase Cardiac Drug Pipeline at H.C. Wainwright Conference

TIPRANKS
·
Sep 09

ProQR Therapeutics doses first participant in AX-0811 clinical trial

TIPRANKS
·
Sep 09

William Blair Initiates Coverage on Obsidian Therapeutics With Outperform Rating

MT Newswires Live
·
Sep 09

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

GlobeNewswire
·
Sep 09

Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15

MT Newswires Live
·
Sep 09

Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates

MT Newswires Live
·
Sep 09

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

GlobeNewswire
·
Sep 09

Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel

TIPRANKS
·
Sep 09

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

GlobeNewswire
·
Sep 09

Summit Therapeutics upgraded to Buy at Jefferies ahead of PFS data

TIPRANKS
·
Sep 09

D. Western Therapeutics Sees FY Loss Y800.00m

Dow Jones
·
Sep 09

Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%

MT Newswires Live
·
Sep 09

Cyclerion Therapeutics trading halted, news pending

TIPRANKS
·
Sep 09